Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10692041rdf:typepubmed:Citationlld:pubmed
pubmed-article:10692041lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:10692041lifeskim:mentionsumls-concept:C0022688lld:lifeskim
pubmed-article:10692041lifeskim:mentionsumls-concept:C0039194lld:lifeskim
pubmed-article:10692041lifeskim:mentionsumls-concept:C2350466lld:lifeskim
pubmed-article:10692041lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:10692041lifeskim:mentionsumls-concept:C1511636lld:lifeskim
pubmed-article:10692041lifeskim:mentionsumls-concept:C1879547lld:lifeskim
pubmed-article:10692041lifeskim:mentionsumls-concept:C0441712lld:lifeskim
pubmed-article:10692041lifeskim:mentionsumls-concept:C0534775lld:lifeskim
pubmed-article:10692041lifeskim:mentionsumls-concept:C1528871lld:lifeskim
pubmed-article:10692041pubmed:issue2lld:pubmed
pubmed-article:10692041pubmed:dateCreated2000-3-15lld:pubmed
pubmed-article:10692041pubmed:abstractTextHuman Valpha24 + NKT cells, a subpopulation of natural killer cell receptor (NKR-P1A) expressing T cells with an invariant T-cell receptor (TCR; Valpha24JalphaQ) are stimulated by the glycolipid, alpha-galactosylceramide (KRN7000), in a CD1d-dependent, TCR-mediated fashion. Little is known about Valpha24 + NKT-cell function. The murine counterpart, Valpha14 + NKT cells, appear to have an important role in controlling malignancy. There are no human data examining the role of Valpha24 + NKT cells in controlling human malignancy. We report that Valpha24 + NKT cells have perforin-mediated cytotoxicity against haemopoietic malignancies. Valpha24 TCR, CD1d and alpha-galactosylceramide may all play a role in cytotoxicity but are not absolute requirements. The greatest cytotoxicity was observed against the U937 tumour cell line (95 +/- 5% lysis). THP-1, Molt4, C1R cells and allogeneic mismatched dendritic cells were also sensitive to Valpha24 + NKT cytotoxicity but neither the NK target, K562, nor lymphokine-activated killer-sensitive Daudi cells, were sensitive. These results indicate a killing pattern distinct from conventional major histocompatibility complex-restricted T cells, NK cells and other cytotoxic lymphoid cells previously described. We conclude that human Valpha24 + NKT cells have cytotoxic anti-tumour activity against haemopoietic malignancies through effector mechanisms distinct from conventional T cells and NK cells and that their specific stimulator KRN7000 may have therapeutic potential.lld:pubmed
pubmed-article:10692041pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10692041pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10692041pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10692041pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10692041pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10692041pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10692041pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10692041pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10692041pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10692041pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10692041pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10692041pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10692041pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10692041pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10692041pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10692041pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10692041pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10692041pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10692041pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10692041pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10692041pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10692041pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10692041pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10692041pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10692041pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10692041pubmed:languageenglld:pubmed
pubmed-article:10692041pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10692041pubmed:citationSubsetIMlld:pubmed
pubmed-article:10692041pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10692041pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10692041pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10692041pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10692041pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10692041pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10692041pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10692041pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10692041pubmed:statusMEDLINElld:pubmed
pubmed-article:10692041pubmed:monthFeblld:pubmed
pubmed-article:10692041pubmed:issn0019-2805lld:pubmed
pubmed-article:10692041pubmed:authorpubmed-author:SuzukiKKlld:pubmed
pubmed-article:10692041pubmed:authorpubmed-author:JujiTTlld:pubmed
pubmed-article:10692041pubmed:authorpubmed-author:TadokoroKKlld:pubmed
pubmed-article:10692041pubmed:authorpubmed-author:NicolAAlld:pubmed
pubmed-article:10692041pubmed:authorpubmed-author:PorcelliSSlld:pubmed
pubmed-article:10692041pubmed:authorpubmed-author:NiedaMMlld:pubmed
pubmed-article:10692041pubmed:authorpubmed-author:DurrantSSlld:pubmed
pubmed-article:10692041pubmed:authorpubmed-author:KoezukaYYlld:pubmed
pubmed-article:10692041pubmed:issnTypePrintlld:pubmed
pubmed-article:10692041pubmed:volume99lld:pubmed
pubmed-article:10692041pubmed:ownerNLMlld:pubmed
pubmed-article:10692041pubmed:authorsCompleteYlld:pubmed
pubmed-article:10692041pubmed:pagination229-34lld:pubmed
pubmed-article:10692041pubmed:dateRevised2010-2-25lld:pubmed
pubmed-article:10692041pubmed:meshHeadingpubmed-meshheading:10692041...lld:pubmed
pubmed-article:10692041pubmed:meshHeadingpubmed-meshheading:10692041...lld:pubmed
pubmed-article:10692041pubmed:meshHeadingpubmed-meshheading:10692041...lld:pubmed
pubmed-article:10692041pubmed:meshHeadingpubmed-meshheading:10692041...lld:pubmed
pubmed-article:10692041pubmed:meshHeadingpubmed-meshheading:10692041...lld:pubmed
pubmed-article:10692041pubmed:meshHeadingpubmed-meshheading:10692041...lld:pubmed
pubmed-article:10692041pubmed:meshHeadingpubmed-meshheading:10692041...lld:pubmed
pubmed-article:10692041pubmed:meshHeadingpubmed-meshheading:10692041...lld:pubmed
pubmed-article:10692041pubmed:meshHeadingpubmed-meshheading:10692041...lld:pubmed
pubmed-article:10692041pubmed:meshHeadingpubmed-meshheading:10692041...lld:pubmed
pubmed-article:10692041pubmed:meshHeadingpubmed-meshheading:10692041...lld:pubmed
pubmed-article:10692041pubmed:meshHeadingpubmed-meshheading:10692041...lld:pubmed
pubmed-article:10692041pubmed:meshHeadingpubmed-meshheading:10692041...lld:pubmed
pubmed-article:10692041pubmed:year2000lld:pubmed
pubmed-article:10692041pubmed:articleTitleHuman invariant valpha24+ natural killer T cells activated by alpha-galactosylceramide (KRN7000) have cytotoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells.lld:pubmed
pubmed-article:10692041pubmed:affiliationQueensland Institute of Medical Research and Department of Medicine, University of Queensland, Royal Brisbane Hospital, Brisbane, Australia.lld:pubmed
pubmed-article:10692041pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10692041pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10692041lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10692041lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10692041lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10692041lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10692041lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10692041lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10692041lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10692041lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10692041lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10692041lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10692041lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10692041lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10692041lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10692041lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10692041lld:pubmed
More...